NEW YORK, May 26, 2026, 18:01 (EDT)
Arrowhead Pharmaceuticals stock climbed about 5% to $78.68 late Tuesday. The rise brought the company’s market cap to roughly $11.2 billion. Arrowhead released new plozasiran data at the European Atherosclerosis Society meeting in Athens. The company said results back using a 25-mg dose, without need for adjustment, in patients with moderate-to-severe kidney issues or moderate liver impairment. “This is an important step,” said Jennifer Hellawell, vice president of clinical development. Arrowhead Pharmaceuticals, Inc.
The readout has new weight because plozasiran got its first FDA nod back in November. Redemplo cleared the agency for familial chylomicronemia syndrome, or FCS, a genetic disease that keeps people from breaking down triglycerides, the fat in blood. The FDA says a normal level is under 150 mg/dL—over 500 mg/dL is considered severely high.
Arrowhead is looking to build out its cardiometabolic lineup after its first launch. In a May 7 update, the company reported more than 400 Redemplo prescriptions received or in progress. CEO Christopher Anzalone called it “strong execution”. Arrowhead also put the U.S. annual wholesale acquisition cost at $45,000, the list price before any rebates or discounts. Arrowhead Pharmaceuticals Inc.
The stock’s move Tuesday happened on an up day for the market. The Nasdaq Composite added 1.19% to 26,656.18 and the S&P 500 was up 0.61% to 7,519.39, with both closing at all-time highs. The Dow lost 0.23%, Reuters said.
U.S. stocks resumed trading after the Memorial Day break. The Nasdaq 2026 holiday calendar puts May 25 as a full market holiday.
Wall Street is divided on whether Arrowhead has already priced in the plozasiran opportunity. Morgan Stanley’s Michael Ulz lifted the stock to Overweight last month with a $100 price target. He told Barron’s that Phase 3 data coming in the third quarter could “unlock a multibillion-dollar opportunity that remains underappreciated.” Barron’s
Bernstein took a more cautious line. In a May 13 note picked up by The Fly, the firm lifted its target to $46 from $35, but left its Market Perform rating unchanged. That target is still below where shares traded Tuesday, flagging valuation risk after the recent rally.
Arrowhead’s latest quarterly filing keeps the biotech flavor in its numbers. The company posted $73.7 million in revenue for the quarter ended March 31, down from $542.7 million the previous year. Net loss attributable to Arrowhead was $132.7 million, flipping from net income of $370.4 million last year. At March 31, total cash resources stood at $1.78 billion, according to the same filing.
Competition is moving fast. On the same day, Sobi—Ionis Pharmaceuticals’ ex-U.S. partner—reported pooled Phase 3 data showing olezarsen cut acute pancreatitis risk by 85% and lowered triglycerides by 66% in severe hypertriglyceridemia after six months. The drug, branded as Tryngolza for FCS, .
Ionis is working against a shorter timeline in the U.S. The FDA has put its supplemental filing for olezarsen in severe hypertriglyceridemia under Priority Review—which moves the process along faster if the drug could give a major benefit. The agency set a target date of June 30. “There is an urgent need for additional treatment options,” CEO Brett Monia said after the designation. Ionis Pharmaceuticals, Inc.
The risk to Arrowhead is clear. The company still has to show strong clinical and commercial results in severe hypertriglyceridemia, and problems in late-stage data, slower patient starts or payer hurdles could hit the stock, which is trading above Bernstein’s latest target. There are also ongoing patent lawsuits between Arrowhead and Ionis over their FCS drugs.
Arrowhead’s next potential move is coming up. The company’s calendar lists a late-breaker poster at the European Association for the Study of the Liver meeting from May 27-30 in Barcelona, featuring ARO-INHBE, its program focused on obesity and liver fat. This isn’t about plozasiran, but the event keeps Arrowhead shares connected to cardiometabolic news for the week.
